Marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense
human African trypanosomiasis, more commonly known as sleeping sickness, has been granted in the Democratic Republic of Congo.
Antimony had been previously used against visceral leishmaniasis, Trypanosoma brucei gambiense
, and yaws.
If the EMA decides to review the treatment, it would be the first all-oral treatment being investigated for Trypanosoma brucei gambiense
human African trypanosomiasis (g-HAT).
The Human African Trypanosomiasis (HAT) is caused by two subspecies of trypanosomes, namely, Trypanosoma brucei gambiense
which is prevalent in west and central Africa and causes chronic disease and T.
However, it has been reported that the anaemia caused by the human infective Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense
in rodents ranges between macrocytic normochromic to microcytic hypochromic anaemia .
Hainard, V Lejon et al., "Cerebrospinal fluid neopterin as marker of the meningo-encephalitic stage of Trypanosoma brucei gambiense
sleeping sickness," PLoS ONE, vol.
Human African trypanosomiasis (HAT) cases are caused by the parasites Trypanosoma brucei gambiense
and Trypanosoma brucei rhodesiense, which are indigenous to west and central Africa.
(2,3) There are two forms of illness: a more chronic infection caused by the protozoan parasite Trypanosoma brucei rhodesiense (West African) and a more acute disease caused by Trypanosoma brucei gambiense
As part of the research, the authors isolated the novel bacterium from the midgut of the tsete fly that also harbours the protozoan Trypanosoma brucei gambiense
(Tbg), responsible for Human African Trypanosomiasis, known as sleeping sickness.
The causative agent of nagana, is closely related to Trypanosoma brucei rhodesiense (which present in East to South Africa) and Trypanosoma brucei gambiense
(which present in West and Central Africa).
According to the World Health Organization (WHO), about 20 Trypanosoma brucei gambiense
and 30 T.